Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients

European Journal of Cancer

Volumn 45, Issue 4, 2009, Pages 572-578

  Kweekel, Dina M ^a   Gelderblom, Hans ^a   Antonini, Ninja F ^b   Van der Straaten, Tahar ^a   Nortier, Johan W R ^a   Punt, Cornelis J A ^c   Guchelaar, Henk Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Colorectal; Glutathione S transferase pi; GSTP1 Ile105Val; Neurotoxicity; Oxaliplatin; Survival

Indexed keywords

CAPECITABINE; GLUTATHIONE TRANSFERASE P1; IRINOTECAN; ISOLEUCINE; OXALIPLATIN; VALINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CODON; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PARESTHESIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PYROSEQUENCING; SENSORY NEUROTOXICITY; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CODON; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; EPIDEMIOLOGIC METHODS; FEMALE; FLUOROURACIL; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 60149087159     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.10.015     Document Type: Article

References (17)

1. Kweekel D.M., Gelderblom H., and Guchelaar H.J. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 31 (2005) 90-105
2. Graham M.A., Lockwood G.F., Greenslade D., Brienza S., Bayssas M., and Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6 (2000) 1205-1218
3. Watson M.A., Stewart R.K., Smith G.B., Massey T.E., and Bell D.A. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19 (1998) 275-280
4. Stoehlmacher J., Park D.J., Zhang W., et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94 (2002) 936-942
5. Ruzzo A., Graziano F., Kawakami K., et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 24 (2006) 1883-1891
6. Goekkurt E., Hoehn S., Wolschke C., et al. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS) - novel predictors for response and survival in gastric cancer patients. Br J Cancer 94 (2006) 281-286
7. Le Morvan V., Smith D., Laurand A., et al. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics 8 (2007) 1693-1703
8. Ruzzo A., Graziano F., Loupakis F., et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25 (2007) 1247-1254
9. Lecomte T., Landi B., Beaune P., Laurent-Puig P., and Loriot M.A. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 12 (2006) 3050-3056
10. Koopman M., Antonini N.F., Douma J., et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370 (2007) 135-142
11. Van Cutsem E., Twelves C., Cassidy J., et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19 (2001) 4097-4106
12. Therasse P., et al., European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
13. Cersosimo R.J. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 39 (2005) 128-135
14. Louvet C., de G.A., Tournigand C., Artru P., Maindrault-Goebel F., and Krulik M. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer 91 (2001) 2033-2038
15. Stoehlmacher J., Park D.J., Zhang W., et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91 (2004) 344-354
16. Caussanel J.P., Levi F., Brienza S., et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 82 (1990) 1046-1050
17. Ishimoto T.M., and li-Osman F. Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics 12 (2002) 543-553